Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Yasushi Ichikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7866-2907; OpenAlex author ID A5013185778, A5015408047. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2013: 1 paper · 2014: 6 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 18

  1. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). Co-author DOI 10.1038/s41598-025-23608-5↗
  2. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulte… Co-author DOI 10.21873/anticanres.17215↗
  3. Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer. Co-author DOI 10.3390/tomography10100117↗
  4. A Case of BRCA2-Pathogenic Variant Breast Cancer With Metachronous Endometrial Cancer and Pancreatic Cancer. Co-author DOI 10.14740/wjon1658↗
  5. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  6. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Last author DOI 10.1016/j.pan.2018.11.001↗
  7. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  8. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Co-author DOI 10.1080/15384101.2017.1315489↗
  9. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Last author DOI 10.1097/md.0000000000006769↗
  10. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model r… Co-author DOI 10.1016/j.pan.2015.02.008↗
  11. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  12. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s12094-013-1079-0↗
  13. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-013-3390-y↗
  14. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. Co-author DOI 10.1371/journal.pone.0103382↗
  15. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combinati… Co-author DOI 10.1371/journal.pone.0114310↗
  16. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenogra… Co-author DOI 10.18632/oncotarget.2641↗
  17. [A case of post-operative recurrence of pancreatic cancer in the residual pancreas treated by resection of the residual pancreas following radiological complet… Last author PMID 25131881↗
  18. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2491-3↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 16 shared papers, 2013–2025 · strength 1.29
  2. Noritoshi Kobayashi · 8 shared papers, 2013–2025 · strength 1.05
  3. Robert M. Hoffman · 8 shared papers, 2014–2024 · strength 0.57
  4. Kensuke Kubota · 4 shared papers, 2013–2025 · strength 0.54
  5. Ryutaro Mori · 5 shared papers, 2014–2025 · strength 0.40
  6. Yukihiko Hiroshima · 8 shared papers, 2013–2020 · strength 0.40
  7. Michael Bouvet · 7 shared papers, 2014–2020 · strength 0.37
  8. Kentaro Miyake · 3 shared papers, 2017–2025 · strength 0.34
  9. Takashi Murakami · 7 shared papers, 2014–2018 · strength 0.31
  10. Atsushi Nakajima · 2 shared papers, 2019–2024 · strength 0.30
  11. Yusuke Kurita · 2 shared papers, 2019–2024 · strength 0.29
  12. Eriko Katsuta · 1 shared paper, 2025 · strength 0.22
  13. Yasuhiro Yabushita · 1 shared paper, 2025 · strength 0.22
  14. Motokazu Sato · 1 shared paper, 2024 · strength 0.20
  15. Sei Morinaga · 1 shared paper, 2024 · strength 0.20
  16. Sho Hasegawa · 1 shared paper, 2024 · strength 0.19
  17. Atsushi Nakajima · 1 shared paper, 2024 · strength 0.19
  18. Shin Maeda · 1 shared paper, 2024 · strength 0.19
  19. Satoshi Fujii · 1 shared paper, 2023 · strength 0.18
  20. Masanori Oshi · 1 shared paper, 2023 · strength 0.18
  21. Yuki Homma · 3 shared papers, 2014–2018 · strength 0.15
  22. Ali A. Maawy · 4 shared papers, 2014–2015 · strength 0.15
  23. Ho Kyoung Hwang · 2 shared papers, 2017–2018 · strength 0.12
  24. Takashi Oshima · 1 shared paper, 2020 · strength 0.10
  25. Yohei Miyagi · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.